Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.
Borad, Mitesh J
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. [electronic resource] - PLoS genetics Feb 2014 - e1004135 p. digital
Publication Type: Journal Article
1553-7404
10.1371/journal.pgen.1004135 doi
Bile Duct Neoplasms--drug therapy
Bile Ducts, Intrahepatic--pathology
Cell Line, Tumor
Cholangiocarcinoma--drug therapy
ErbB Receptors--antagonists & inhibitors
Erlotinib Hydrochloride
Genome, Human
Humans
Imidazoles--administration & dosage
Indazoles
Molecular Targeted Therapy
Mutation
Prognosis
Protein Kinase Inhibitors
Pyridazines--administration & dosage
Pyrimidines--administration & dosage
Quinazolines--administration & dosage
Receptor, Fibroblast Growth Factor, Type 2--antagonists & inhibitors
Signal Transduction--genetics
Sulfonamides--administration & dosage
Transcriptome
Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. [electronic resource] - PLoS genetics Feb 2014 - e1004135 p. digital
Publication Type: Journal Article
1553-7404
10.1371/journal.pgen.1004135 doi
Bile Duct Neoplasms--drug therapy
Bile Ducts, Intrahepatic--pathology
Cell Line, Tumor
Cholangiocarcinoma--drug therapy
ErbB Receptors--antagonists & inhibitors
Erlotinib Hydrochloride
Genome, Human
Humans
Imidazoles--administration & dosage
Indazoles
Molecular Targeted Therapy
Mutation
Prognosis
Protein Kinase Inhibitors
Pyridazines--administration & dosage
Pyrimidines--administration & dosage
Quinazolines--administration & dosage
Receptor, Fibroblast Growth Factor, Type 2--antagonists & inhibitors
Signal Transduction--genetics
Sulfonamides--administration & dosage
Transcriptome